Home

Versant Vantage I, L.P.

CIK 1765253 · last filed 2025-09-18

Versant Vantage I, L.P. is a corporate insider who has filed 12 SEC Form 4 insider transactions across 7 companies since 2020. The most recent filing shows the insider sold $15.0M of LVTX on Sep 18, 2025. Across all open-market trades the lifetime net is −$113.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $126.3M across reported positions. The firm reports its address in San Francisco, CA. 48 SEC filings were submitted jointly with Versant Venture Capital VI, L.P.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$126.34M

Companies

7

Total Filings

12

Lifetime Open-Market Net

-$113.67M

Filer Profile

Reported Address
ONE SANSOME, SUITE 1650
SAN FRANCISCO, CA 94104
Phone
(415) 801-8100
State of Incorporation
DE
Related Filers
Versant Venture Capital VI, L.P. — 48 joint filings, latest 2025-09-23
Versant Vantage I GP, L.P. — 36 joint filings, latest 2025-09-23
Versant Vantage I GP-GP, LLC — 36 joint filings, latest 2025-09-23
Versant Ventures VI GP, L.P. — 23 joint filings, latest 2025-09-23
Versant Ventures VI GP-GP, LLC — 23 joint filings, latest 2025-09-23
Versant Voyageurs I Parallel, L.P. — 23 joint filings, latest 2024-08-30
Versant Voyageurs I, L.P. — 23 joint filings, latest 2024-08-30
Versant Side Fund IV, L.P. — 11 joint filings, latest 2024-04-11
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
LAVA Therapeutics NV (LVTX) Delisted 10%+ Owner 3,358,920 $1.74 $5.84M -$15.01M 1 2025-09-18
GLUE 10%+ Owner 8,355,156 $14.07 $117.56M -$20.43M 1 2024-09-13
BDTX 10%+ Owner 4,107,283 $1.98 $8.13M -$10.78M 5 2024-08-30
Oyster Point Pharma, Inc. (OYST) Delisted 10%+ Owner 2,243,406 $11.17 $25.06M -$73.45M 1 2021-10-20
Repare Therapeutics Inc. (RPTX) Delisted 10%+ Owner 2,825,662 $2.65 $7.49M $0 2 2021-08-09
ALGS 10%+ Owner 123,694 $5.22 $645.7K $6.00M 1 2020-10-20
APRE 10%+ Owner 10,833 $0.77 $8.4K $0 1 2020-05-20

Recent Filings

12 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2025-09-18 LAVA Therapeutics NV (LVTX) Delisted Sell (S) −10,106,604 -$15.01M EDGAR
2024-09-13 GLUE Sell (S) −3,403,278 -$20.43M EDGAR
2024-08-30 BDTX Sell (S) −886,400 -$5.60M EDGAR
2021-10-20 Oyster Point Pharma, Inc. (OYST) Delisted Sell (S) −4,950,000 -$73.45M EDGAR
2021-08-09 Repare Therapeutics Inc. (RPTX) Delisted Other (J) −456,213 $0 EDGAR
2021-02-18 Repare Therapeutics Inc. (RPTX) Delisted Other (J) −1,050,000 $0 EDGAR
2020-12-01 BDTX Mixed −1,742,272 -$1.38M EDGAR
2020-11-06 BDTX Sell (S) −45,392 -$1.50M EDGAR
2020-10-20 ALGS Mixed +6,584,678 $6.00M EDGAR
2020-10-15 BDTX Sell (S) −68,960 -$2.30M EDGAR
Showing 1–10 of 12
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.